The Resource Development of PRO-140 (Leronlimab) as a treatment for COVID-19, Jacob Lalezari, (streaming video)
Development of PRO-140 (Leronlimab) as a treatment for COVID-19, Jacob Lalezari, (streaming video)
Resource Information
The item Development of PRO-140 (Leronlimab) as a treatment for COVID-19, Jacob Lalezari, (streaming video) represents a specific, individual, material embodiment of a distinct intellectual or artistic creation found in University of Liverpool.This item is available to borrow from 1 library branch.
Resource Information
The item Development of PRO-140 (Leronlimab) as a treatment for COVID-19, Jacob Lalezari, (streaming video) represents a specific, individual, material embodiment of a distinct intellectual or artistic creation found in University of Liverpool.
This item is available to borrow from 1 library branch.
- Language
- eng
- Extent
- 1 online resource (1 streaming audio file (20 min.)).
- Note
-
- Audio interview
- Title from title frames
- Contents
-
- Contents: Previous indications for Leronlimab
- Leronlimab is a CCR5 receptor antagonist
- CCR5 receptor function in inflammation and disease
- Clinical limitations of blocking CCR5 receptors
- How will Leronlimab be used in the clinic?
- When can we expect a preliminary approval?
- Label
- Development of PRO-140 (Leronlimab) as a treatment for COVID-19
- Title
- Development of PRO-140 (Leronlimab) as a treatment for COVID-19
- Statement of responsibility
- Jacob Lalezari
- Language
- eng
- Accompanying matter
- technical information on music
- Cataloging source
- UkLoHST
- http://library.link/vocab/creatorName
- Lalezari, Jacob,
- Series statement
- Research and clinical interviews,
- http://library.link/vocab/subjectName
-
- Coronavirus infections
- COVID-19 (Disease)
- Drug development
- CCR5 Receptor Antagonists
- Coronavirus Infections
- COVID-19
- Drug Development
- Inflammation
- leronlimab
- Pharmaceutical Preparations
- Receptors, CCR5
- severe acute respiratory syndrome coronavirus 2
- Label
- Development of PRO-140 (Leronlimab) as a treatment for COVID-19, Jacob Lalezari, (streaming video)
- Note
-
- Audio interview
- Title from title frames
- Color
- not applicable
- Configuration of playback channels
- monaural
- Contents
- Contents: Previous indications for Leronlimab -- Leronlimab is a CCR5 receptor antagonist -- CCR5 receptor function in inflammation and disease -- Clinical limitations of blocking CCR5 receptors -- How will Leronlimab be used in the clinic? -- When can we expect a preliminary approval?
- Control code
- HST8159
- Dimensions
-
- unknown
- not applicable
- Extent
- 1 online resource (1 streaming audio file (20 min.)).
- Form of item
- online
- Groove width / pitch
- not applicable
- Kind of cutting
- not applicable
- Kind of disc cylinder or tape
- not applicable
- Kind of material
- other
- Publisher number
- 8159
- Sound
- sound
- Special playback characteristics
- digital recording
- Specific material designation
- remote
- System control number
- (UkLoHST)4246
- Tape configuration
- not applicable
- Tape width
- not applicable
- Label
- Development of PRO-140 (Leronlimab) as a treatment for COVID-19, Jacob Lalezari, (streaming video)
- Note
-
- Audio interview
- Title from title frames
- Color
- not applicable
- Configuration of playback channels
- monaural
- Contents
- Contents: Previous indications for Leronlimab -- Leronlimab is a CCR5 receptor antagonist -- CCR5 receptor function in inflammation and disease -- Clinical limitations of blocking CCR5 receptors -- How will Leronlimab be used in the clinic? -- When can we expect a preliminary approval?
- Control code
- HST8159
- Dimensions
-
- unknown
- not applicable
- Extent
- 1 online resource (1 streaming audio file (20 min.)).
- Form of item
- online
- Groove width / pitch
- not applicable
- Kind of cutting
- not applicable
- Kind of disc cylinder or tape
- not applicable
- Kind of material
- other
- Publisher number
- 8159
- Sound
- sound
- Special playback characteristics
- digital recording
- Specific material designation
- remote
- System control number
- (UkLoHST)4246
- Tape configuration
- not applicable
- Tape width
- not applicable
Subject
- COVID-19
- COVID-19 (Disease)
- Coronavirus Infections -- drug therapy
- Coronavirus infections -- Research
- Drug Development
- Drug development
- Inflammation
- Pharmaceutical Preparations
- Receptors, CCR5
- leronlimab
- severe acute respiratory syndrome coronavirus 2
- CCR5 Receptor Antagonists -- therapeutic use
Member of
- Henry Stewart talks, Biomedical & life sciences collection | Research and clinical interviews
- Online access with subscription: Henry Stewart talks (Biomedical and Life Sciences)
Library Links
Embed
Settings
Select options that apply then copy and paste the RDF/HTML data fragment to include in your application
Embed this data in a secure (HTTPS) page:
Layout options:
Include data citation:
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.liverpool.ac.uk/portal/Development-of-PRO-140-Leronlimab-as-a/JUkstlZ8Z6Y/" typeof="Book http://bibfra.me/vocab/lite/Item"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.liverpool.ac.uk/portal/Development-of-PRO-140-Leronlimab-as-a/JUkstlZ8Z6Y/">Development of PRO-140 (Leronlimab) as a treatment for COVID-19, Jacob Lalezari, (streaming video)</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.liverpool.ac.uk/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.liverpool.ac.uk/">University of Liverpool</a></span></span></span></span></div>
Note: Adjust the width and height settings defined in the RDF/HTML code fragment to best match your requirements
Preview
Cite Data - Experimental
Data Citation of the Item Development of PRO-140 (Leronlimab) as a treatment for COVID-19, Jacob Lalezari, (streaming video)
Copy and paste the following RDF/HTML data fragment to cite this resource
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.liverpool.ac.uk/portal/Development-of-PRO-140-Leronlimab-as-a/JUkstlZ8Z6Y/" typeof="Book http://bibfra.me/vocab/lite/Item"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.liverpool.ac.uk/portal/Development-of-PRO-140-Leronlimab-as-a/JUkstlZ8Z6Y/">Development of PRO-140 (Leronlimab) as a treatment for COVID-19, Jacob Lalezari, (streaming video)</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.liverpool.ac.uk/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.liverpool.ac.uk/">University of Liverpool</a></span></span></span></span></div>
